Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma
- PMID: 16436637
- PMCID: PMC1867577
- DOI: 10.2353/jmoldx.2006.040402
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma
Abstract
Recent studies have shown the hedgehog and Wnt families of signaling proteins to be associated with tumor initiation, growth, and survival. However, these pathways remain unexplored in ovarian endometrioid adenocarcinoma (OEA). Here, we describe a novel TaqMan low-density array to examine the expression of 26 and 20 genes in the hedgehog and Wnt pathways, respectively, in six matched snap-frozen and formalin-fixed, paraffin-embedded (FPE) OEA specimens. Expression values were normalized to uninvolved ovarian epithelium. Gene expression in matched frozen and FPE tissues demonstrated significant concordance (r = 0.92, P < 0.0001). However, comparison of amplified and unamplified RNA from frozen OEA tissues revealed an altered molecular profile in amplified RNA. Amplification of RNA from FPE tissues was not successful. The expression of Desert hedgehog (DHH), Indian hedgehog (IHH), Hedge-hog interacting protein (HHIP), Wnt10B, Wnt9B, and Wnt inhibitory factor (WIF1) were tumor-specific with no detectable expression in normal ovarian epithelium. In addition, several genes were significantly (P < 0.025) down-regulated in OEA, including cyclin E2, Porcupine, c-Myc, and Axin 2 (4.8-, 3.6-, 2.9-, and 1.9-fold, respectively). TaqMan low-density array provides an effective multivariate technique for examining gene expression in RNA isolated from either snap-frozen or archival FPE tissues and can identify tumor-specific genes, possibly leading to novel treatments.
Figures




Similar articles
-
Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.Cancer Res. 2003 Jun 1;63(11):2913-22. Cancer Res. 2003. PMID: 12782598
-
Multiple gene expression analyses in human lymphoid tissues by taqman low-density array using amplified rna isolated from paraffin-embedded samples.Diagn Mol Pathol. 2009 Sep;18(3):156-64. doi: 10.1097/PDM.0b013e3181917560. Diagn Mol Pathol. 2009. PMID: 19704261
-
Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues.Diagn Mol Pathol. 2007 Jun;16(2):61-72. doi: 10.1097/PDM.0b013e31802f0804. Diagn Mol Pathol. 2007. PMID: 17525674
-
Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies.Diagn Mol Pathol. 2007 Dec;16(4):229-37. doi: 10.1097/PDM.0b013e31811edc7e. Diagn Mol Pathol. 2007. PMID: 18043287
-
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.Cancer Cell. 2007 Apr;11(4):321-33. doi: 10.1016/j.ccr.2007.02.016. Cancer Cell. 2007. PMID: 17418409
Cited by
-
Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch.PLoS One. 2012;7(10):e45606. doi: 10.1371/journal.pone.0045606. Epub 2012 Oct 22. PLoS One. 2012. PMID: 23110045 Free PMC article.
-
Biomarkers and the genetics of early neoplastic lesions.Cancer Biomark. 2010;9(1-6):41-64. doi: 10.3233/CBM-2011-0204. Cancer Biomark. 2010. PMID: 22112469 Free PMC article. Review.
-
Quality management of biorepositories.Biopreserv Biobank. 2015 Jun;13(3):183-94. doi: 10.1089/bio.2014.0105. Biopreserv Biobank. 2015. PMID: 26035008 Free PMC article.
-
Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.Cell Div. 2010 Jan 17;5:2. doi: 10.1186/1747-1028-5-2. Cell Div. 2010. PMID: 20180967 Free PMC article.
-
Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.Cancer Biol Ther. 2010 Nov 1;10(9):893-902. doi: 10.4161/cbt.10.9.13252. Epub 2010 Nov 1. Cancer Biol Ther. 2010. PMID: 20814245 Free PMC article.
References
-
- Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33. - PubMed
-
- Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Holzel D. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 2002;38:2435–2445. - PubMed
-
- Goodman MT, Correa CN, Tung KH, Roffers SD, Cheng Wu X, Young JL, Jr, Wilkens LR, Carney ME, Howe HL. Stage at diagnosis of ovarian cancer in the United States, 1992–1997. Cancer. 2003;97:2648–2659. - PubMed
-
- McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996;23:40–47. - PubMed
-
- Wicking C, Smyth I, Bale A. The hedgehog signalling pathway in tumorigenesis and development. Oncogene. 1999;18:7844–7851. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous